BioNTech, Bristol Myers Squibb Announced Sunday At ESMO, Phase 2 ROSETTA Lung-107 Data Showing Pumitamig + Docetaxel Achieved 36.7% Confirmed Objective Response Rate, 90% Disease Control Rate, 6.9-Month Median PFS In Previously Treated Metastatic NSCLC
Share
Why It Matters
Two drug companies shared test results for a new cancer treatment combination. When doctors saw patients get better, it hints the medicine might work well enough to help real people someday.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.